Catalent(CTLT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CTLT Catalent

盘前交易 11-22 09:27:10 EST

59.66

+0.66

+1.12%

盘前59.66

+0.000.00%

09:12 EST

最高59.84	最低58.92	成交量119.00万
今开59.09	昨收59.00	日振幅1.57%
总市值108.29亿	流通市值107.62亿	总股本1.82亿
成交额7,095万	换手率0.66%	流通股本1.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CTLT","market":"US","secType":"STK","nameCN":"Catalent","latestPrice":59.66,"timestamp":1732222800000,"preClose":59,"halted":0,"volume":1190016,"hourTrading":{"tag":"盘前","latestPrice":59.66,"preClose":59.66,"latestTime":"09:12 EST","volume":1,"amount":59.66,"timestamp":1732284737647},"delay":0,"floatShares":180392022,"shares":181511586,"eps":-2.280772,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.66,"latestTime":"11-22 09:27:10 EST","open":59.09,"high":59.84,"low":58.915,"amount":70949520.290304,"amplitude":0.015678,"askPrice":61,"askSize":1,"bidPrice":59.62,"bidSize":60,"shortable":3,"etf":0,"ttmEps":-2.280772,"exchange":"NYSE","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732285800000},"adr":0,"listingDate":1406779200000,"adjPreClose":59.66,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":59.66,"preClose":59.66,"latestTime":"09:12 EST","volume":1,"amount":59.66,"timestamp":1732284737647},"postHourTrading":{"tag":"盘后","latestPrice":59.66,"preClose":59.66,"latestTime":"18:28 EST","volume":19200,"amount":1145472,"timestamp":1732231692789},"volumeRatio":0.8407138539407039,"impliedVol":0.4835,"impliedVolPercentile":0.8606},"requestUrl":"/m/hq/s/CTLT","defaultTab":"news","newsList":[{"id":"2484647678","title":"BUZZ-巴克莱认为 2025 年欧盟制药业前景充满挑战，看好诺和诺德与阿斯利康","url":"https://stock-news.laohu8.com/highlight/detail?id=2484647678","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484647678?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:44","pubTimestamp":1731926697,"startTime":"0","endTime":"0","summary":"BUZZ-巴克莱认为 2025 年欧盟制药业前景充满挑战，看好诺和诺德与阿斯利康11月18日 -  ** 巴克莱认为，2025年欧盟制药业的前景充满挑战，理由是防御性行业将出现宏观轮动。** 近期大型制药公司情绪低落，医疗保健行业以外的市场前景不断改善，这表明 2025 年欧盟制药业的表现不会优于市场。** 该经纪商更看好诺和诺德NOVOb.CO和阿斯利康AZN.L，对这两家公司保持 \"增持 \"评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP0OJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2091194634.USD","LU1153584641.USD","IE00BFTCPJ56.SGD","IE0034235188.USD","LU0158827948.USD","LU1267930490.SGD","LU0047473722.EUR","LU1989771016.USD","LU0122379950.USD","LU0640478417.SGD","LU1487256676.USD","LU1267930227.SGD","LU0972486137.USD","LU0757432116.USD","03165","IE0009355771.USD","IE0002141913.USD","LU1261432733.SGD","LU0029864427.USD","LU1267930813.SGD","LU2114397693.USD","LU1481600234.SGD","LU0997586432.USD","BK4585","LU0957799991.USD","LU0889565080.SGD","LU1989772923.USD","LU0823416689.USD","LU0496365809.HKD","LU1051770623.HKD","LU0345777147.USD","LU2089984988.USD","LU0203347892.USD","LU2023251221.USD","SG9999001176.SGD","LU0823399737.USD","LU1057294990.SGD","CTLT","LU1019634622.SGD","AZN.UK","LU1267930573.SGD","LU1983299246.USD","SG9999001176.USD","LU1019632923.USD","LU0661504455.SGD","LU0708994859.HKD","LU0889566641.SGD","LU0211327993.USD","LU0211326839.USD","LU2089284900.SGD"],"gpt_icon":0},{"id":"2483340838","title":"欧盟监管机构就 165 亿美元交易质询诺和诺德和康泰伦特竞争对手","url":"https://stock-news.laohu8.com/highlight/detail?id=2483340838","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483340838?lang=zh_cn&edition=full","pubTime":"2024-11-14 01:21","pubTimestamp":1731518461,"startTime":"0","endTime":"0","summary":"欧盟监管机构已将初步审查的截止日期定在 12 月 6 日。这项价值 165 亿美元的交易  于今年 2 月宣布，凸显了诺和诺德提高每周注射一次的 Wegovy 产量的决心。交易完成后，诺和诺德控股公司将以 110 亿美元的价格把康泰伦特在意大利、比利时和美国的三个灌装工厂出售给诺和诺德。诺和诺德控股公司、诺和诺德公司和康泰伦特公司最近都重申，他们预计这项交易将于今年年底完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE0009355771.USD","LU0203201768.USD","LU0154236417.USD","LU0417517546.SGD","LU1035775433.USD","LU0354030511.USD","LU0106261372.USD","BK4007","LU0203202063.USD","IE0004445239.USD","CTLT","LU0079474960.USD","LU0058720904.USD","LU0114720955.EUR","LU0456855351.SGD","LU0471298777.SGD","LU1061106388.HKD","LLY","LU0882574055.USD","BK4581","LU0708995401.HKD","LU0820561909.HKD","IE00B4R5TH58.HKD","BK4532","LU0109391861.USD","LU0289739699.SGD","LU0238689110.USD","LU1023059063.AUD","LU1057294990.SGD","LU0689472784.USD","IE00BJT1NW94.SGD","IE00BZ1G4Q59.USD","LU0882574139.USD","LU0943347566.SGD","LU1093756325.SGD","LU0006306889.USD","LU0061475181.USD","LU0471298694.HKD","NVO","IE0002141913.USD","LU1064131342.USD","BK4533","LU0256863902.USD","IE00BJLML261.HKD","LU0820561818.USD","LU0385154629.USD","LU1069344957.HKD","BK4534","LU0198837287.USD"],"gpt_icon":1},{"id":"2481509482","title":"康泰伦特第一季度营收不及预期，与诺和控股的 165 亿美元交易即将完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2481509482","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481509482?lang=zh_cn&edition=full","pubTime":"2024-11-05 21:21","pubTimestamp":1730812917,"startTime":"0","endTime":"0","summary":"诺和诺德的控股投资公司 Novo Holdings 于今年 2 月同意收购康泰伦特，以增加 Wegovy 的供应。背景 康泰伦特表示，该交易预计将于今年年底完成，之后母公司将以 110 亿美元的价格向诺和诺德出售这家合同制造商的三个关键灌装-成品工厂。数字 根据 LSEG 统计的数据，康泰伦特在截至 9 月 30 日的第一财季实现营收 10.2 亿美元，略低于分析师预计的 10.6 亿美元。药品和消费者健康部门的销售额为 5.63 亿美元，低于预期的 5.666 亿美元。康泰伦特季度调整后每股亏损 13 美分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTLT"],"gpt_icon":0},{"id":"2480798573","title":"欧盟将于12月6日前对诺和诺德作出裁决","url":"https://stock-news.laohu8.com/highlight/detail?id=2480798573","media":"智通财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480798573?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:57","pubTimestamp":1730710637,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据欧盟委员会网站周一发布的文件，欧盟反垄断监管机构将在12月6日之前决定是否批准诺和诺德收购美国合同制药商Catalent。文件显示，诺和诺德控股股东于10月31日向欧盟提交了批准该交易的请求。欧盟反垄断监管机构可以在有或没有补救措施的情况下批准这笔交易，也可以在有严重担忧的情况下展开为期4个月的全面调查。此次收购于今年2月宣布，突显了丹麦制药商诺和诺德提高其畅销减肥药Wegovy产量的努力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104170309ab9de4d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"c8930b257377b3ad681bfe33e024f8d5","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104170309ab9de4d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LLY","LU1093756168.USD","LU1093756325.SGD","IE00BKVL7J92.USD","LU0154236417.USD","BK4530","BK4585","CTLT","BK4588","IE00BZ1G4Q59.USD","BK4007","NVO","BK4532"],"gpt_icon":1},{"id":"2480379492","title":"欧盟将于12月6日前对诺和诺德(NVO.US)收购Catalent(CTLT.US)作出裁决","url":"https://stock-news.laohu8.com/highlight/detail?id=2480379492","media":"智通财经网","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480379492?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:57","pubTimestamp":1730710637,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据欧盟委员会网站周一发布的文件，欧盟反垄断监管机构将在12月6日之前决定是否批准诺和诺德收购美国合同制药商Catalent。文件显示，诺和诺德控股股东于10月31日向欧盟提交了批准该交易的请求。此次收购于今年2月宣布，突显了丹麦制药商诺和诺德提高其畅销减肥药Wegovy产量的努力。诺和诺德和Catalent最近都重申了它们的预期，即交易将在今年年底前完成。诺和诺德在肥胖和糖尿病药物市场的主要竞争对手礼来也表达了担忧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4532","LU1093756168.USD","IE00BKVL7J92.USD","NVO","BK4007","LLY","CTLT","BK4585","BK4588","BK4530","LU0154236417.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD"],"gpt_icon":1},{"id":"2480320101","title":"欧盟反垄断监管机构将于 12 月 6 日前就诺和诺德收购康泰伦特一事做出决定","url":"https://stock-news.laohu8.com/highlight/detail?id=2480320101","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480320101?lang=zh_cn&edition=full","pubTime":"2024-11-04 15:54","pubTimestamp":1730706871,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透布鲁塞尔11月4日 - 据欧盟执委会网站周一发布的一份文件显示，欧盟反垄断监管机构将在12月6日前决定是否批准诺和诺德收购合同药品生产商康泰伦特  的交易。文件显示，诺和诺德  的控股股东于10月31日向欧盟提出了批准该交易的申请。欧盟反垄断机构既可以在采取或不采取补救措施的情况下批准该交易，也可以在严重关切的情况下展开长达四个月的全面调查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c8930b257377b3ad681bfe33e024f8d5","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4530","BK4588","BK4585","BK4007","CTLT","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","LU1093756325.SGD","LU0154236417.USD"],"gpt_icon":0},{"id":"2478262473","title":"赛诺菲首席财务官称不会受到诺和诺德康泰伦特交易的影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2478262473","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478262473?lang=zh_cn&edition=full","pubTime":"2024-10-25 13:54","pubTimestamp":1729835660,"startTime":"0","endTime":"0","summary":"    路透法兰克福10月25日 - 赛诺菲  财务总监周五表示，该公司不会受到诺和诺德  控股股东收购合同药品生产商康泰伦特<Catalent    的决定的影响，并补充说这笔交易对其竞争对手是有意义的。\"赛诺菲首席财务官弗朗索瓦-格扎维埃-罗杰在第三季度财报发布后的媒体电话会议上说：\"他们迫切需要产能，所以这对他们来说是有意义的， 。他补充说，鉴于减肥药的需求非常旺盛，诺和诺德为获得产能付出了 \"非常沉重的代价\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU0456855351.SGD","LU0820561818.USD","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU0466842654.USD","LU0094547139.USD","LU0354030511.USD","LU0417517546.SGD","LU0203201768.USD","IE0009355771.USD","IE00BJT1NW94.SGD","LU0154236417.USD","LU1061106388.HKD","BK4585","LU1093756168.USD","CTLT","BK4534","LU0471298777.SGD","BK4530","LU0238689110.USD","LU1035775433.USD","BK4516","LU0689472784.USD","LU0203202063.USD","BK4532","LU0256863811.USD","IE00BZ1G4Q59.USD","IE0002141913.USD","BK4007","IE00BK4W5L77.USD","LU0006306889.USD","LU0943347566.SGD","IE00B1BXHZ80.USD","IE00B4R5TH58.HKD","BK4533","LU0289739699.SGD","LLY","LU0385154629.USD","LU0256863902.USD","LU0061475181.USD","LU0106261372.USD","LU0882574139.USD","LU0672654240.SGD","LU1064131342.USD","IE00B2B36J28.USD","LU0096364046.USD","LU0823416689.USD","NVO","IE0004445239.USD"],"gpt_icon":0},{"id":"2477558597","title":"更新版 4-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477558597","media":"路透中文","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477558597?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 4-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 11 和 12 段增加了诺和诺德的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官称，有关部门应阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4T3LZ15P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTLT","BK4550","VKTX","LU0964806797.USD","SGXZ57979304.SGD","LU0972486137.USD","LU0289739699.SGD","SG9999013999.USD","LU0047473722.EUR","AZN.UK","LU0661504455.SGD","IE000M9KFDE8.USD","LU0757432116.USD","LU0321505868.SGD","LU0738911758.USD","LU0882574055.USD","LU1066051498.USD","LU0211326755.USD","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","BK5011","LU0211327993.USD","LU0957799991.USD","IE00BJJMRZ35.SGD","LU0868494617.USD","BK4530","GPCR","LU0784385840.USD","LU1066053197.SGD","LU0211328371.USD","SG9999002224.SGD","LU0553294199.USD","BK4139","LU0310800965.SGD","LU0345777659.USD","LU0823399737.USD","LU1061106388.HKD","BK4007","LU0058720904.USD","BK4566","LU1883839398.USD","LU0122379950.USD","BK4533","IE00BFTCPJ56.SGD","AMGN","IE00BLSP4452.SGD","PFE","LU0557290698.USD","SG9999001176.USD","03165"],"gpt_icon":1},{"id":"2477558594","title":"更新版 4-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477558594","media":"路透中文","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477558594?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 4-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 11 和 12 段增加了诺和诺德的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官称，有关部门应阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4S3LZ15P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211328371.USD","LU0661504455.SGD","IE00BJT1NW94.SGD","LU0964806797.USD","AZN.UK","BK4139","LU0757432116.USD","AMGN","IE00BFTCPJ56.SGD","LU0289739699.SGD","IE00BLSP4452.SGD","LU0868494617.USD","CTLT","LU0321505868.SGD","BK4566","LU0738911758.USD","IE00BJJMRZ35.SGD","BK4533","LU0345777659.USD","SG9999013999.USD","LU1061106388.HKD","BK5011","BK4530","LU0957799991.USD","IE000M9KFDE8.USD","LU1066053197.SGD","PFE","LU0784385840.USD","GPCR","IE00B19Z3B42.SGD","SGXZ57979304.SGD","LU0058720904.USD","LU0823399737.USD","LU1883839398.USD","03165","LU0972486137.USD","SG9999002224.SGD","LU0310800965.SGD","LU0882574055.USD","LU0553294199.USD","LU0211326755.USD","LU1066051498.USD","VKTX","SG9999001176.USD","BK4550","LU0122379950.USD","LU0211327993.USD","LU0557290698.USD","BK4007","LU0047473722.EUR"],"gpt_icon":1},{"id":"2477539245","title":"更新版 3-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477539245","media":"路透中文","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477539245?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 3-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 6 段增加了首席执行官的评论，第 13 段增加了康泰伦特的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官说，有关部门应该阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4S3LZ15P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK5011","BK4530","IE00B2B36J28.USD","LU0345777659.USD","CTLT","LU0011850046.USD","LU0211327993.USD","LU0310800379.SGD","LU0792757196.USD","BK4007","BK4568","LU0234572021.USD","LU0225284248.USD","LU0963555726.SGD","IE00BJT1NW94.SGD","LU0972486137.USD","LU0557290698.USD","LU1057294990.SGD","LU0128525929.USD","LU0170899867.USD","LU0203347892.USD","LU0052756011.USD","LU1061106388.HKD","LU0109394709.USD","LU0708994859.HKD","LU0122379950.USD","AMGN","LU0823416689.USD","LU0969580561.USD","LU0949170772.SGD","BK4566","LU0320765992.SGD","PFE","LU0203345920.USD","LU0526926950.USD","VKTX","LU0985481810.HKD","LU0114720955.EUR","IE000M9KFDE8.USD","LU0321505439.SGD","AZN.UK","LU0128525689.USD","IE00BJJMRZ35.SGD","SG9999002232.USD","GPCR","LU0211326755.USD","IE0002141913.USD","03165","LU0949170426.SGD","BK4139"],"gpt_icon":1},{"id":"2477017843","title":"更新版 2-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477017843","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477017843?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"尽管罗氏公司周三强调自己没有受到影响，但它是首批表示反对这项交易的制药商之一，这项交易可能会对蓬勃发展的肥胖症药物行业产生广泛影响。诺和诺德、诺和控股和康泰伦特没有立即回应置评请求。上周，当被要求就康泰伦特交易的审查发表评论时，罗氏公司表示，未来肥胖症药物的商业化生产将同时采用内部和外部生产方式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","BK4585","BK4532","BK4007","BK4588","NVO","IE00BKVL7J92.USD","WRD","LU1093756325.SGD","IE00BZ1G4Q59.USD","CTLT","LU1093756168.USD","BK4530"],"gpt_icon":0},{"id":"2477778663","title":"更新版 1-罗氏公开反对清仓收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477778663","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477778663?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:35","pubTimestamp":1729672509,"startTime":"0","endTime":"0","summary":"  Ludwig Burger    路透法兰克福10月23日 - 制药巨头罗氏  的首席执行官敦促当局阻止诺和诺德  的控股股东收购合同药品生产商康泰伦特  ，理由是会损害行业同行的利益。上周，美国消费者团体和工会向美国联邦贸易委员会请愿，要求阻止  诺和诺德的控股股东诺和控股收购康泰伦特，称该交易威胁到减肥药和尖端基因疗法领域的竞争。罗氏此前曾表示，未来将采用内部和外部生产相结合的方式进行肥胖症药物的商业化生产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CTLT","BK4007","BK4588","BK4530"],"gpt_icon":0},{"id":"2477792376","title":"罗氏首席执行官公开反对批准收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477792376","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477792376?lang=zh_cn&edition=full","pubTime":"2024-10-23 15:41","pubTimestamp":1729669274,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透法兰克福10月23日 - 瑞士制药巨头罗氏  的首席执行官说，竞争管理机构不应允许诺和诺德  的控股股东收购合同药品生产商康泰伦特  。\"这对我们来说不是问题，但对其他小企业来说可能是个问题，如果对(合同制造商)。罗氏公司首席执行官托马斯-希内克尔（Thomas Schinecker）在季度销售额公布后的媒体电话会议上说：\"从行业角度看，这将是当局的一个错误决定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTLT","BK4530","BK4585","BK4588","BK4007"],"gpt_icon":0},{"id":"2477855315","title":"诺和诺德完成收购后，康泰伦特首席执行官将继续掌管合同药品生产商","url":"https://stock-news.laohu8.com/highlight/detail?id=2477855315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477855315?lang=zh_cn&edition=full","pubTime":"2024-10-21 19:12","pubTimestamp":1729509161,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透10月21日 - 康泰伦特  总裁兼首席执行官亚历山德罗-马塞利（Alessandro Maselli）周一表示，在减肥药生产商诺和诺德  的控股股东诺和诺德控股公司收购康泰伦特后，他将继续领导这家合同药品生产商。马塞利的公开信是在对诺和诺德收购康泰伦特的批评日益增多的背景下发出的，该收购可能威胁到减肥药和尖端基因疗法领域的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","NVO","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4588","BK4532","BK4585","LU0154236417.USD","CTLT","BK4530","IE00BKVL7J92.USD","BK4007"],"gpt_icon":0},{"id":"2476375401","title":"减肥药扩产计划遇阻！美国消费者团体要求FTC阻止诺和诺德","url":"https://stock-news.laohu8.com/highlight/detail?id=2476375401","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476375401?lang=zh_cn&edition=full","pubTime":"2024-10-18 17:33","pubTimestamp":1729243990,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，美国消费者团体和两个大型工会敦促美国联邦贸易委员会阻止诺和诺德股东Novo Holdings收购合同药品制造商Catalent Inc.，称该交易威胁到减肥药和尖端基因疗法领域的竞争。这三座工厂专门从事药品的无菌灌装，预计将从2026年起逐步增加诺和诺德的灌装能力。当地时间周四下午，十个消费者团体签署了这封信。不过，所涉及的Catalent工厂与Novo Holdings计划出售给诺和诺德的三家工厂并不相关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410181735119f4cecaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410181735119f4cecaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4530","BK4588","CTLT","LU1093756325.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","NVO","LU1093756168.USD","BK4532","FTC","BK4007"],"gpt_icon":0},{"id":"2476416906","title":"消费者团体要求美国FTC阻止Novo Holdings收购Catalent的交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2476416906","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476416906?lang=zh_cn&edition=full","pubTime":"2024-10-18 10:35","pubTimestamp":1729218957,"startTime":"0","endTime":"0","summary":"据路透，美国消费者团体和两大工会周四敦促美国联邦贸易委员会(FTC)阻止诺和诺德控股股东Novo Holdings收购合同药物制造商Catalent，称该交易威胁减肥药和尖端基因疗法领域的竞争。美国公共利益研究组织、服务业雇员国际工会(SEIU)和其他组织在一封致FTC的信中表达了对这笔价值165亿美元交易的担忧。上周，美国民主党参议员沃伦呼吁FTC密切关注这笔交易，理由也是类似的担忧。该交易可能会限制安进、辉瑞、罗氏和阿斯利康等竞争对手的选择，据报道，这些竞争对手正在开发GLP-1药物。\n\n\r\n            责任编辑：栎树","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/10/18103544144055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["CTLT","FTC","BK4007","BK4588","BK4585","BK4530"],"gpt_icon":0},{"id":"2476486769","title":"消费者团体要求美国联邦贸易委员会阻止诺和诺德控股公司与卡塔伦特公司的交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2476486769","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476486769?lang=zh_cn&edition=full","pubTime":"2024-10-18 02:00","pubTimestamp":1729188006,"startTime":"0","endTime":"0","summary":"        *      消费者团体和工会向美国联邦贸易委员会表达竞争担忧        *      交易可能会限制开发 GLP-1 药物的竞争对手的选择        *      对基因疗法生产的影响也引起了关注   Jody Godoy/Maggie Fick    路透纽约10月17日 - 五个美国消费者团体和两个大型工会周四敦促美国联邦贸易委员会阻止诺和诺德公司  的控股股东收购合同药品制造商康泰伦特  ，称该交易威胁到减肥药和尖端基因疗法领域的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","GPCR","LU2112291526.USD","LU1057294990.SGD","LU0320765992.SGD","SRPT","IE0002270589.USD","LU1894683264.USD","LU0456855351.SGD","SG9999001176.SGD","BK4533","IE00BBT3K403.USD","IE00BLSP4239.USD","LU0321505868.SGD","LU1023059063.AUD","SG9999011175.SGD","SGXZ57979304.SGD","LU2242646821.SGD","BK4592","BK4581","LU0109394709.USD","IE00BFTCPJ56.SGD","SG9999013999.USD","LU0058720904.USD","NVO","SG9999001176.USD","LU1894683348.USD","LU0170899867.USD","IE0002141913.USD","LU0321505439.SGD","AMGN","LU0225284248.USD","LU0289739699.SGD","LU0868494617.USD","CTLT","LU0225771236.USD","IE00BJJMRZ35.SGD","VKTX","LU1061106388.HKD","LU0889565916.HKD","LLY","BK4534","IE00BJT1NW94.SGD","BK4532","SG9999003800.SGD","LU1093756168.USD","BK4588","BK4139","LU1983299246.USD","LU0306806265.USD"],"gpt_icon":1},{"id":"2475721362","title":"今日优惠-合并与收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2475721362","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475721362?lang=zh_cn&edition=full","pubTime":"2024-10-14 21:44","pubTimestamp":1728913465,"startTime":"0","endTime":"0","summary":"今日优惠-合并与收购添加：H Lundbeck A/S, ASMPT, Catalent, InPost 更新：B. Riley、Young Poong、韩华集团路透10月14日 - 截至格林尼治标准时间周一13:30，报道了以下竞购、兼并、收购和处置： ** B. Riley RILY.O已同意将其评估和估值服务部门Great American出售给资产管理公司橡树资本，交易金额为3.86亿美元。nL4N3LQ0MI  ** 私募股权公司MBK和Young Poong 000670.KS在一份监管文件中称，通过已结束的要约收购，MBK和Young Poong获得了韩国锌业010130.KS超过5%的股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241014:nL4S3LQ0ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NO4.SI","IE00B775SV38.USD","BK1169","BK4585","LU1282649810.SGD","LU0348767384.USD","MUL.UK","IE00B3S45H60.SGD","LU2039709279.SGD","IE00B66KJ199.SGD","LU0417516902.SGD","BK4135","LU0348783233.USD","RILY","LU1282649141.HKD","LU1813983027.USD","FRAS.UK","BN","IE00B7SZL793.SGD","IE0031619046.USD","LU0227179875.USD","BK5145","BK4007","BK6504","LU1282649067.USD","LU0348825331.USD","LU0274383008.USD","00522","BK1589","LU0348766576.USD","IE00B19Z4B17.USD","BK4588","LBPH","CTLT","LU0348784397.USD","BK6088","LU0384037296.USD","LU0314109678.HKD","LU0417516571.SGD","LU1328277881.USD","BK5147","LU0648948544.HKD","LU0488056044.USD","BK4530","BK4127"],"gpt_icon":0},{"id":"2475336274","title":"今日优惠-合并与收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2475336274","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475336274?lang=zh_cn&edition=full","pubTime":"2024-10-14 21:44","pubTimestamp":1728913465,"startTime":"0","endTime":"0","summary":"今日优惠-合并与收购添加：H Lundbeck A/S, ASMPT, Catalent, InPost 更新：B. Riley、Young Poong、韩华集团路透10月14日 - 截至格林尼治标准时间周一13:30，报导了以下竞购、兼并、收购和处置： ** B. Riley RILY.O已同意将其评估和估值服务部门Great American出售给资产管理公司橡树资本，交易金额为3.86亿美元。nL4N3LQ0MI  ** 私募股权公司MBK和Young Poong 000670.KS在一份监管文件中称，通过已结束的要约收购，MBK和Young Poong获得了韩国锌业010130.KS超过5%的股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241014:nL4T3LQ0ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314109678.HKD","BK4585","BK4007","RILY","MUL.UK","LU0274383008.USD","LU0417516571.SGD","00522","LU0227179875.USD","LU0348766576.USD","LU0488056044.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","LU0348784397.USD","BK6504","LU0384037296.USD","LU0417516902.SGD","LU0648948544.HKD","LU1282649810.SGD","LU0348825331.USD","BK5145","BK5147","LU1328277881.USD","BN","BK4588","BK4127","BK4135","LU1813983027.USD","IE00B19Z4B17.USD","BK1169","BK1589","LU2039709279.SGD","FRAS.UK","BK6088","LBPH","IE0031619046.USD","IE00B775SV38.USD","LU1282649141.HKD","IE00B3S45H60.SGD","LU0348783233.USD","CTLT","NO4.SI","LU1282649067.USD","LU0348767384.USD","BK4530"],"gpt_icon":0},{"id":"2475560363","title":"Catalent将出售新泽西工厂","url":"https://stock-news.laohu8.com/highlight/detail?id=2475560363","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475560363?lang=zh_cn&edition=full","pubTime":"2024-10-14 19:59","pubTimestamp":1728907161,"startTime":"0","endTime":"0","summary":"金吾财讯 | Catalent 已同意将其位于新泽西州萨默塞特的口服药物开发和小规模制造工厂出售给私人合同药品制造商 Ardena。Catalent 为包括丹麦制药巨头诺和诺德的药物 Wegovy 在内的制药商提供合同制造服务并执行灌装工作，涉及注射器和注射笔的无菌灌装和包装。拥有诺和诺德控股权的投资公司 Novo Holdings 于 2 月份签署了一项价值 165 亿美元的协议收购 Catalent，以增加 Wegovy 的供应，预计该交易将于今年年底完成。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"280858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4585","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4007","LU0154236417.USD","NVO","BK4588","LU1093756325.SGD","CTLT","IE00BKVL7J92.USD","BK4530"],"gpt_icon":0}],"profile":{"websiteUrl":"http://catalent.com","stockEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":-0.0043},{"period":"3month","weight":0.0037},{"period":"6month","weight":0.0883},{"period":"1year","weight":0.5066},{"period":"ytd","weight":0.3278}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Catalent, Inc.是全球领先的药物先进递送技术和开发制造解决方案提供商；蛋白质、细胞和基因治疗生物制品以及消费健康产品。该公司的口服、注射、细胞和基因治疗以及细胞和呼吸输送技术解决了制药行业的全面多样性，包括小分子；蛋白质、细胞和基因治疗生物制品；以及消费健康产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.058226},{"month":2,"riseRate":0.6,"avgChangeRate":0.038189},{"month":3,"riseRate":0.4,"avgChangeRate":0.009076},{"month":4,"riseRate":0.6,"avgChangeRate":0.013795},{"month":5,"riseRate":0.5,"avgChangeRate":0.014479},{"month":6,"riseRate":0.6,"avgChangeRate":0.020877},{"month":7,"riseRate":0.8,"avgChangeRate":0.082712},{"month":8,"riseRate":0.636364,"avgChangeRate":0.009563},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.037618},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.028945},{"month":11,"riseRate":0.636364,"avgChangeRate":0.011617},{"month":12,"riseRate":0.5,"avgChangeRate":0.002741}],"exchange":"NYSE","name":"Catalent","nameEN":"Catalent"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Catalent(CTLT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Catalent(CTLT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Catalent,CTLT,Catalent股票,Catalent股票老虎,Catalent股票老虎国际,Catalent行情,Catalent股票行情,Catalent股价,Catalent股市,Catalent股票价格,Catalent股票交易,Catalent股票购买,Catalent股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Catalent(CTLT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Catalent(CTLT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}